89bio, Inc. Skyrocketed
Thu, Sep 18, 2025 at 08:00 PM
89bio, Inc. (ETNB:NASDAQ) jumped higher at $14.96, a gain of 85.1%. On Thu, Sep 18, 2025, ETNB:NASDAQ touched a New 2-Week High of $14.96. The stock appeared on our News Catalysts scanner on Thu, Sep 18, 2025 at 03:45 PM in the 'ACQUISITION' category. From Thu, Sep 04, 2025, the stock recorded 50.00% Up Days and 36.36% Green Days
About 89bio, Inc. (ETNB:NASDAQ)
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Top 10 Gainers:
- Brera Holdings PLC (BREA:NASDAQ), 225.49%
- Adaptimmune Therapeutics plc (ADAP:NASDAQ), 98.02%
- Cardlytics, Inc. (CDLX:NASDAQ), 92.66%
- 89bio, Inc. (ETNB:NASDAQ), 85.15%
- SRAX, Inc. (SRAX:NASDAQ), 75%
- Laser Photonics Corporation (LASE:NASDAQ), 68.21%
- Aeries Technology, Inc (AERT:NASDAQ), 63.85%
- Psyence Biomedical Ltd. (PBM:NASDAQ), 42.47%
- Aptevo Therapeutics Inc. (APVO:NASDAQ), 40.43%
- Robot Consulting Co. Ltd. (LAWR:NASDAQ), 35.64%